Dabigatran etexilate analogue with fluorine-containing group modified pyridine ring as center and synthesis method of analogue

Abstract

The invention discloses a dabigatran etexilate analogue with fluorine-containing group modified pyridine ring as a center and a synthesis method of the analogue. According to the synthesis method, with a fluorine-containing group aminopyridine compound as a starting material, a series of reactions are carried out to prepare he fluorine-containing group modified dabigatran etexilate analogue. The synthesis method of the analogue has the advantages that the operation is simple, used reagents are low in cost and easily available, synthesis cost is relatively low, rick in the synthetic process is low, yield of each synthesis step is high, and synthesis time is short.

Description

technical field [0001] The invention relates to a dabigatran etexilate analog centered on a pyridine ring modified by a fluorine-containing group and a synthesis method thereof, belonging to the field of chemical synthesis. Background technique [0002] The direct thrombin inhibitor dabigatran etexilate (dabigatrau etexilate, trade name Pradaxa) was developed by Boehringer Ingelheim, Germany, and was first launched in Germany and the UK in April 2008. It is a new type, non-peptide, competitive , a reversible thrombin inhibitor, after being taken orally and absorbed by the gastrointestinal tract, it will be converted into dabigatran with direct anticoagulant activity in the body, and its structural diagram is shown in figure 1 shown. [0003] The structural representation of dabigatran etexilate is as follows: figure 2 As shown, dabigatran etexilate is the first new category of oral anticoagulant drugs listed on the market in 50 years after warfarin. Medication monitoring...

AI Technical Summary

Problems solved by technology

[0004] But dabigatran etexilate still has the following defects as direct coagulant at present: the oral bioavailability of dabigatran etexilate is low

[0006] At present, dabigatran etexilate has low bioavailability, bleeding will occur during anticoagulant therapy, especially when used in high doses, the incidence of bleeding is higher and other technical problems

And in its preparation process, the key steps also need to use volatile and toxic HCl, NH 3 and other gases, so the preparation cost is high, and the preparation process is very dangerous

Such as CN200610082286.8 in the preparation of compound 3-({2-[(4-imido-phenylimine)-methylene]-1-methylene-1 hydrogen-benzimidazole-5-carbonyl}-[4 -Fluorobenzene]-2-imine)-propionate ethyl ester, using volatile and toxic HCl, NH 3 and other gases, which increases the danger of the preparation process

Images